Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-A445 Alone or With Tislelizumab in Advanced Solid Tumors
NCT05661955Phase 2Active, not recruiting
- Sponsor
- BeiGene
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of gimistotug in urothelial carcinoma (UC), renal cell carcinoma (RCC) and melanoma, sponsored by BeiGene. Primary endpoint: Overall Response Rate at 26 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
gimistotug
03
Conditions
urothelial carcinoma (UC)renal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on NCT05661955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661955.